PDMR Dealing / Grant of Share Options
Oxford BioDynamics Plc has granted 170,000,000 share options to employees and advisers, including directors, at an exercise price of 0.61 pence per share, a 100% premium to the previous day's closing price. Of these, 119,000,000 options are for directors and PDMRs and will vest monthly over 24 months, while the remaining 51,000,000 options will vest in three tranches with immediate vesting for 20% and further vesting on November 10, 2026, and November 10, 2027, for the rest. The Executive Chairman, Iain Ross, received 44,000,000 options, and other directors and PDMRs received 15,000,000 options each.
Select text to share a quote on X · sign in to keep highlights & notes in your OBD notes
Oxford BioDynamics Plc (AIM: OBD, the Company), a precision clinical diagnostics company bringing specific and sensitive tests to the practice of medicine based on its EpiSwitch® 3D genomics platform, announces that it has today granted a total of 170,000,000 options over its ordinary shares of 0.1 pence each ("Ordinary Shares"), to Group employees and advisers, including certain directors and PDMRs of the Company, as outlined in the table below.
The options were granted under the Company's 2016 Employee and Non-Employee Share Option Plans with an exercise price of 0.61p per share, representing a premium of 100% over the closing share price on 7 November 2025, the business day immediately preceding the grant of the options.
119,000,000 options granted to directors and PDMRs will vest monthly in 24 equal tranches to 10 November 2027.
51,000,000 options will vest in three tranches: 20% will vest immediately and will be exercisable from six months after the date of grant; 40% will vest and become exercisable on 10 November 2026; and 40% will vest and become exercisable on 10 November 2027.
Vested options will remain exercisable up to and including the tenth anniversary of the date of grant.
The grants made to directors and PDMRs of the Company were as follows:
| New options granted | Total number of options over Ordinary Shares | Ordinary Shares held* | ||
|---|---|---|---|---|
| Number | % of current issued share capital | |||
| Iain Ross, Executive Chairman | 44,000,000 | 140,000,000 | 23,333,333 | 0.54 |
| Alexandre Akoulitchev, Chief Scientific Officer | 15,000,000 | 34,596,131 | 14,228,962 | 0.33 |
| David Blum, SVP of Marketing | 15,000,000 | 33,462,500 | 744,611 | 0.02 |
| Thomas Guiel, Chief Operations Officer | 15,000,000 | 33,650,000 | 6,288,146 | 0.15 |
| Ewan Hunter, Chief Data Officer | 15,000,000 | 33,660,000 | 722,754 | 0.02 |
| Paul Stockdale, Chief Financial Officer | 15,000,000 | 33,980,000 | 6,411,252 | 0.15 |
*Shareholdings are stated following allotments pursuant to the recent fundraising. Percentages are calculated with reference to the Company's Enlarged Share Capital following General Admission, which is expected to take place on 11 November 2025.
The notifications below, made in accordance with the requirements of UK Market Abuse Regulation, provide further details:
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |
| a) | Name | Alexandre Akoulitchev |
| 2 | Reason for the notification | |
| a) | Position/status | Director/PDMR |
| b) | Initial notification/ Amendment | Initial notification |
| a) | Name | Oxford BioDynamics Plc |
| b) | LEI | 2138005Y1TK258O5U928 |
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of 0.1 pence each ISIN: GB00BD5H8572 |
| b) | Nature of the transaction | Grant of share options |
| c) | Price(s) and volume(s) | 15,000,000 ordinary shares at an exercise price of 0.61 pence per share |
| d) | Aggregated information - Aggregated volume - Price | N/A |
| e) | Date of the transaction | 10 November 2025 |
| f) | Place of the transaction | Outside a trading venue |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |
| a) | Name | David Blum |
| 2 | Reason for the notification | |
| a) | Position/status | PDMR |
| b) | Initial notification/ Amendment | Initial notification |
| a) | Name | Oxford BioDynamics Plc |
| b) | LEI | 2138005Y1TK258O5U928 |
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of 0.1 pence each ISIN: GB00BD5H8572 |
| b) | Nature of the transaction | Grant of share options |
| c) | Price(s) and volume(s) | 15,000,000 ordinary shares at an exercise price of 0.61 pence per share |
| d) | Aggregated information - Aggregated volume - Price | N/A |
| e) | Date of the transaction | 10 November 2025 |
| f) | Place of the transaction | Outside a trading venue |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |
| a) | Name | Thomas Guiel |
| 2 | Reason for the notification | |
| a) | Position/status | PDMR |
| b) | Initial notification/ Amendment | Initial notification |
| a) | Name | Oxford BioDynamics Plc |
| b) | LEI | 2138005Y1TK258O5U928 |
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of 0.1 pence each ISIN: GB00BD5H8572 |
| b) | Nature of the transaction | Grant of share options |
| c) | Price(s) and volume(s) | 15,000,000 ordinary shares at an exercise price of 0.61 pence per share |
| d) | Aggregated information - Aggregated volume - Price | N/A |
| e) | Date of the transaction | 10 November 2025 |
| f) | Place of the transaction | Outside a trading venue |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |
| a) | Name | Ewan Hunter |
| 2 | Reason for the notification | |
| a) | Position/status | PDMR |
| b) | Initial notification/ Amendment | Initial notification |
| a) | Name | Oxford BioDynamics Plc |
| b) | LEI | 2138005Y1TK258O5U928 |
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of 0.1 pence each ISIN: GB00BD5H8572 |
| b) | Nature of the transaction | Grant of share options |
| c) | Price(s) and volume(s) | 15,000,000 ordinary shares at an exercise price of 0.61 pence per share |
| d) | Aggregated information - Aggregated volume - Price | N/A |
| e) | Date of the transaction | 10 November 2025 |
| f) | Place of the transaction | Outside a trading venue |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |
| a) | Name | Iain Ross |
| 2 | Reason for the notification | |
| a) | Position/status | Director/PDMR |
| b) | Initial notification/ Amendment | Initial notification |
| a) | Name | Oxford BioDynamics Plc |
| b) | LEI | 2138005Y1TK258O5U928 |
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of 0.1 pence each ISIN: GB00BD5H8572 |
| b) | Nature of the transaction | Grant of share options |
| c) | Price(s) and volume(s) | 44,000,000 ordinary shares at an exercise price of 0.61 pence per share |
| d) | Aggregated information - Aggregated volume - Price | N/A |
| e) | Date of the transaction | 10 November 2025 |
| f) | Place of the transaction | Outside a trading venue |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |
| a) | Name | Paul Stockdale |
| 2 | Reason for the notification | |
| a) | Position/status | Director/PDMR |
| b) | Initial notification/ Amendment | Initial notification |
| a) | Name | Oxford BioDynamics Plc |
| b) | LEI | 2138005Y1TK258O5U928 |
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of 0.1 pence each ISIN: GB00BD5H8572 |
| b) | Nature of the transaction | Grant of share options |
| c) | Price(s) and volume(s) | 15,000,000 ordinary shares at an exercise price of 0.61 pence per share |
| d) | Aggregated information - Aggregated volume - Price | N/A |
| e) | Dates of the transactions | 10 November 2025 |
| f) | Place of the transaction | Outside a trading venue |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.